At SKIM we have learned from studies over the past few years, that not only lower costs but also many complex factors need to be considered in order to determine future impact of biosimilars.

Understanding how these factors will influence uptake and how this may evolve over time will be essential for originator companies to build effective strategies across therapy areas, settings, and countries.

In this presentation we shared our views on how market research and analytics can help forecast and impact the uptake of biosimilars in different market situations.

We put these views into practice by sharing learnings and challenges from a recent uptake study in the area of rheumatology among physicians and pharmacists.